LENSAR, Inc. (LNSR) Stock Price, Financials & Summary

Price chart

Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16

Key dataOct 16, 2026

Open$6.09

From 52W high−54.44%

Volume73651.00

Market cap$71.26M

P/E (TTM)4.6x

P/S (TTM)1.2x

Div yield—

Key dataOct 16, 2026

Open

$6.09

From 52W high

−54.44%

Volume

73651.00

Market cap

$71.26M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.6x

P/E (TTM)

4.6x

RSI (14)

25.7

MomentumView details →

1D Return

−3.81%

YTD Return

−49.34%

SummaryUpdated Jun 1, 2026

LENSAR, Inc. (NASDAQ:LNSR) is a commercial-stage medical device company founded in 2004 and headquartered in Orlando, Florida. The company went public in October 2020 and specializes in developing femtosecond laser systems for cataract surgery and corneal astigmatism management. LENSAR has established itself as a significant player in the laser-assisted cataract surgery market, with approximately 21% market share in the United States and over 385 systems installed globally as of 2024.

Ask drillr about LENSAR, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

4.6x

EV/EBITDA

1.6x

EV/Sales

1.0x

P/S (TTM)

1.2x

P/B (TTM)

4.8x

ProfitabilityView details →

Gross Margin

47.96%

Net Margin

57.57%

EBITDA Margin

60.51%

ROE (TTM)

232.78%

ROA (TTM)

49.88%

Asset Turnover

0.89x

GrowthView details →

Revenue YoY

+3.26%

EPS YoY

+130.17%

FCF YoY

−40.06%

Revenue CAGR 3Y

+18.23%

EPS CAGR 3Y

−5.13%

EBITDA YoY

+233.27%

MomentumView details →

1D Return

−3.81%

YTD Return

−49.34%

1Y Return

−50.28%

RSI (14)

25.7

vs 50D SMA

−20.49%

vs 200D SMA

−23.86%

Capital & dividendView details →

Debt/Equity

0.16x

Current Ratio

2.39x

Quick Ratio

1.13x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.10

EPS Surprise

160.61%

Beats (12Q)

5/12

Next Q EPS Est

−$0.07

Avg Surprise (4Q)

153.28%

Rev Surprise

−6.58%

Financials snapshotView financials →

Revenue (TTM)

60.26M

Net Income (TTM)

34.70M

Op. CF (TTM)

−7.29M

Next earningsNov 12, 2026 →

Latest newsMore news →

LENSAR, Inc. reported its financial results for the second quarter of 2026, with recurring revenue of $13.7 million and 10 ALLY Robotic Cataract Laser System placements, bringing the total laser installed base to 445 systems.64d ago

Similar companies

electroCore, Inc.ECOR Outset Medical, Inc.OM Pulmonx CorporationLUNG Hyperfine, Inc.HYPR Lucid Diagnostics Inc.LUCD Envoy Medical, Inc.COCH Find similar companies →

Latest newsMore news →